UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 6,784 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 5.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 134,334 shares of the company’s stock after purchasing an additional 6,784 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.13% of Dyne Therapeutics worth $4,825,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of DYN. Nisa Investment Advisors LLC increased its holdings in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics during the third quarter worth $34,000. US Bancorp DE increased its stake in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Dyne Therapeutics in the third quarter valued at about $62,000. Finally, KBC Group NV lifted its position in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after buying an additional 751 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DYN. Royal Bank of Canada began coverage on Dyne Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price target on the stock. Morgan Stanley upped their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Finally, Piper Sandler reissued an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.82.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $27.47 on Thursday. Dyne Therapeutics, Inc. has a 52-week low of $10.33 and a 52-week high of $47.45. The business’s 50 day simple moving average is $30.68 and its two-hundred day simple moving average is $35.30. The firm has a market cap of $2.80 billion, a P/E ratio of -7.72 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Insider Activity

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,334 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares of the company’s stock, valued at $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now directly owns 98,568 shares in the company, valued at $3,405,524.40. This trade represents a 1.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 180,046 shares of company stock worth $6,300,265. 20.77% of the stock is owned by company insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.